Sudeep Pharma IPO Details: Everything You Should Know about 

Check Expert’s Verdicts on Sudeep Pharma IPO

The Sudeep Pharma IPO will be open for bidding from 21st November to 25th November. It is a book-building issue of 895.00 crore shares, comprising a fresh issue of 0.16 crore shares, and an offer for sale of 1.35 crore shares. The IPO is expected to be listed on the BSE and NSE, with a tentative listing date of 28th November 2025.

Sudeep Pharma IPO Details

The Sudeep Pharma IPO is expected to take place from 21st November 2025 to 25th November 2025. The face value of Sudeep Pharma IPO shares is ₹1 per share, and the IPO price is set at ₹563.00 to ₹593.00 per share.

MUFG Intime India Private Limited is the registrar of the Sudeep Pharma IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below.

Sudeep Pharma IPO Details 

Sudeep Pharma IPO Share Reservation

Sudeep Pharma’ IPO is a book-building issue IPO of 500 Crore shares. Sudeep Pharma Limited Shares will be listed on the BSE and the NSE. Furthermore, SEBI has specified the share reservation criteria for different investor categories.

Sudeep Pharma IPO GMP 

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Would you like to receive live updates on the Sudeep Pharma IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of 21st November 2025, the Sudeep Pharma IPO GMP stands at ₹45 per share, indicating that the share is likely to list at ₹638 on its tentative listing date, 28th November 2025.

GMP data is subject to change based on market trends and sentiments. Please verify the live GMP status before applying for the Sudeep Pharma IPO GMP. Stay informed with Univest for real-time insights into IPOs and their GMP trends. 

Sudeep Pharma IPO Review

Review the detailed Sudeep Pharma IPO review for a thorough understanding of its potential to deliver listing gains. The Sudeep Pharma IPO review will help you invest effectively to avoid significant losses. Explore more to make an informed Investment decision on this IPO.

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Therefore, it is crucial to comprehend the business’s economic performance and trends before applying for the Sudeep Pharma IPO.

Sudeep Pharma Limited’s revenue increased by 10% from ₹465.38 crore in March 2024 to ₹511.33 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹133.15 crores to ₹138.69 crores. Investors can analyse other relevant factors and make a decision accordingly.

Sudeep Pharma Limited’s IPO has shown consistent revenue growth, indicating the company’s financial stability. Moreover, brokers, investors, and RAs have a positive outlook for Sudeep Pharma’s IPO on its tentative listing day.

Technical Analysis

Some technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Sudeep Pharma IPO

The P/E ratio of Sudeep Pharma Limited’s shares is 47.61, and its Earnings Per Share (EPS) is 12.46. Thus, the Sudeep Pharma Limited IPO can deliver gains on its tentative listing day, 28th November 2025

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Sudeep Pharma Limited are subject to change after the IPO. Refer to the table below for post-issue updates on these two metrics. 

Sudeep Pharma IPO Subscription Status

 The subscription status for the Sudeep Pharma IPO is yet to be announced. Stay informed on this passage to check the live Sudeep Pharma IPO subscription status. 

About the Sudeep Pharma Limited Company Overview

Sudeep Pharma was established in 1989 and is a manufacturer of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients serving over 100 countries. The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. The company supplies over 200 products to a diverse customer base across the pharmaceutical, food, and nutrition sectors. The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.

• Market leadership with a diversified product portfolio in a high-barrier industry
• Distinguished global customer base with long-standing relationships with key customers
• Well-equipped and regulatory-compliant Manufacturing Facilities
• Intense research and development capabilities

Sudeep Pharma Limited Financials

The company’s financial analysis is essential before applying for Sudeep Pharma Limited’s IPO. Refer to the table to learn about Sudeep Pharma Limited’s financial information. 

Explanation

Sudeep Pharma Limited’s revenue increased by 10% from ₹465.38 crore in March 2024 to ₹511.33 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹133.15 crores to ₹138.69 crores. Investors can analyse other relevant factors and make a decision accordingly.

Sudeep Pharma IPO Promoter Holdings

Take a look at the table below to review the holdings of Sudeep Pharma Limited’s promoters.

Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust.

Note: The value will be calculated using Equity Dilution = Share Holding Pre-Issue –  Share Holding Post-Issue.

Sudeep Pharma IPO Objectives

The primary objective of the Sudeep Pharma IPO is to raise ₹895.00 crore. However, before applying for the IPO, it is essential to be aware of its secondary objectives. 

• Capital expenditure towards the procurement of machinery for the production line located at the Nandesari Facility.
• General corporate purposes

Should I Invest in Sudeep Pharma IPO?

Explore the pros and cons of Sudeep Pharma IPO to decide whether to apply for it or avoid it. These pros and cons might help you understand the IPO’s potential to deliver profits in the coming decades.

Pros of Sudeep Pharma IPO

• Strong financial performance, characterised by healthy revenue and profit growth.
• Diversified product portfolio serving the pharma, food, and nutrition industries.
• Large and reputable customer base, including global brands.
• Expansion-focused use of IPO funds to increase manufacturing capacity.
• Three established manufacturing facilities enable scalable operations.

Cons of the Sudeep Pharma IPO

• Significant offer-for-sale portion indicating promoter dilution.
• High dependency on key customers poses concentration risk.
• All plants are located in one region, increasing geographical risk.
• Capex execution delays could impact future growth.
• Regulatory and quality compliance lapses could affect business stability.

How to Invest in the Sudeep Pharma IPO?

Please follow the steps outlined below to apply for a position at Sudeep Pharma IPO Limited.

• Step 1: Conduct thorough research on the Sudeep Pharma IPO, including GMP status, subscription status, issue size, lot size, and other relevant details. 
• Step 2: Open a demat account with Univest to gain real-time insights into GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Place a bid for one lot of 25 shares, valued at ₹15,000.
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Sudeep Pharma IPO across multiple demat accounts to increase your chances of allotment. 

How to Check Sudeep Pharma IPO Allotment Status?

You can check for the Sudeep Pharma IPO allotment in different ways. These include NSE and the registrar portal. Follow the steps below to check your allotment status online.

Check On NSE

• Visit the NSE Official Website.
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose the Sudeep Pharma IPO.  
• Choose whether to proceed with the PAN number or the application number.
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal. 
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Sudeep Pharma IPO allotment status.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts 

Sudeep Pharma’s IPO is a Boobuilding IPO of ₹895.00 crore. The shares of Sudeep Pharma IPO Limited will be listed on the BSE and NSE on its tentative listing date of 28th November 2025. Researching the Sudeep Pharma IPO, including its GMP status and reviews, is highly recommended to secure the desired profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Stay informed with Univest to get regular updates on the Sudeep Pharma IPO, GMP, subscription, and more!

FAQs on Sudeep Pharma IPO

How is the Sudeep Pharma IPO?

Ans. As of 21st November 2025, the Sudeep Pharma IPO GMP (Grey Market Premium) stands at 45. It indicates that the estimated listing price could be ₹638 per share. It is a book-building IPO of 895 crore shares. The face value of each share of Sudeep Pharma IPO Limited is ₹1.

What is the Sudeep Pharma IPO price?

Ans. The Sudeep Pharma IPO price range is ₹563.00 to ₹593.00 per share. Retail investors can apply for a minimum of 1 lot, each consisting of 25 shares, worth ₹14,825. Moreover, HNIs are required to bid for a minimum of 14 lots  (350 shares) worth ₹2,07,550.

Is the Sudeep Pharma IPO a good investment?

Ans. Sudeep Pharma Limited’s revenue increased by 10% from ₹465.38 crore in March 2024 to ₹511.33 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹133.15 crores to ₹138.69 crores. Investors can analyse other relevant factors and make a decision accordingly.

Who will be the registrar of the Sudeep Pharma IPO?

Ans. According to recent updates, MUFG Intime India Private Limited will be the registrar responsible for managing allotment and refund procedures. For any queries regarding the Sudeep Pharma IPO GMP, allotment, or refund, please contact MUFG Intime India Private Limited at ipo.helpdesk@linkintime.co.in or +91-22-4918 6270.

What is the issue size of the Sudeep Pharma IPO?  

Ans. Sudeep Pharma IPO is a book-building issue of 895.00 crore. Moreover, the IPO is set to open on 21st November 2025 and close on 25th November 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Sudeep Pharma IPO, wait for the Sudeep Pharma IPO RHP and Sudeep Pharma IPO DRHP. Conduct thorough research before investing in IPOs to minimise the risk of significant losses. You can also consult your financial advisor.

Upcoming IPOs

Current & Previous IPOs

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

Also Explore

Univest Screeners